Rituximab therapy for membranous nephropathy: A systematic review

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 4, 2009, Pages 734-744

  Bomback, Andrew S ^a   Derebail, Vimal K ^a   McGregor, Julie G ^a   Kshirsagar, Abhijit V ^a   Falk, Ronald J ^a   Nachman, Patrick H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHONIA; FACE RASH; FATIGUE; FOLLOW UP; HAIR DISEASE; HAIR LOSS; HAIR THINNING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LARYNX SPASM; LUNG ADENOCARCINOMA; MEDLINE; MEMBRANOUS GLOMERULONEPHRITIS; MYALGIA; NAUSEA; PROTEINURIA; PRURITUS; REMISSION; RIGOR; SEPTICEMIA; SERUM SICKNESS; SIDE EFFECT; SORE THROAT; SWEATING; SYSTEMATIC REVIEW; WHEEZING; ADULT; DRUG ADMINISTRATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 66449124496     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05231008     Document Type: Article

References (49)

1. Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23: 324-332, 2003
2. Swaminathan S, Leung N, Lager DJ, Melton LJ III, Bergstralh EJ, Rohlinger A, Fervenza FC: Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30- year renal biopsy study. Clin J Am Soc Nephrol 1: 483-487, 2006
3. Fervenza FC, Sethi S, Specks U: Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 3: 905-919, 2008
4. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G: Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am J Kidney Dis 44: 385-401, 2004 (Pubitemid 39164615)
5. Cattran D: Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol 16: 1188-1194, 2005 (Pubitemid 41716503)
6. Kerjaschki D, Neale TJ: Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7: 2518-2526, 1996 (Pubitemid 27469557)
7. Cohen CD, Calvaresi N, Armelloni S, Schmid H, Henger A, Ott U, Rastaldi MP, Kretzler M: CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 18: 328-333, 2005 (Pubitemid 41078956)
8. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001
9. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC: Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66: 1199-1205, 2004 (Pubitemid 39121029)
10. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
11. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003
12. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, Ferrara JL, Uberti JP: Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9: 505-511, 2003
13. Fra GP, Avanzi GC, Bartoli E: Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 12: 783-787, 2003
14. Rossi P, Demoux AL, Granel B, Bagneres D, Bonin-Guillaume S, Frances Y: Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy. Rheumatology (Oxford) 44: 403-405, 2005 (Pubitemid 40361304)
15. Rao PS: Nephrotic syndrome in patients with peripheral blood stem cell transplant. Am J Kidney Dis 45: 780-785, 2005 (Pubitemid 40460768)
16. Srinivasan R, Balow JE, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y, Austin H, Tisdale J, Barrett J, Geller N, Childs R: Nephrotic syndrome: An under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol 131: 74-79, 2005 (Pubitemid 43899711)
17. Jacobson SH, van Vollenhoven R, Gunnarsson I: Rituximab- induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant 21: 1742-1743, 2006 (Pubitemid 43834662)
18. Cobo M, Hernandez D, Rodriguez C, Perez-Tamajon L: Successful therapeutic use of rituximab in refractory membranous glomerulonephritis. Clin Nephrol 66: 54-57, 2006 (Pubitemid 44043733)
19. Gallon L, Chhabra D: Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 6: 3017-3021, 2006
20. Reddy P, Johnson K, Uberti JP, Reynolds C, Silver S, Ayash L, Braun TM, Ratanatharathorn V: Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 38: 351-357, 2006
21. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cravedi P, Bontempelli M, Remuzzi G: Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol 1: 738-748, 2006
22. Terrier B, Delmas Y, Hummel A, Presne C, Glowacki F, Knebelmann B, Combe C, Lesavre P, Maillard N, Noel LH, Patey-Mariaud de Serre N, Nusbaum S, Radford I, Buzyn A, Fakhouri F: Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: Clinical presentation, outcome and pathogenic aspects. Nephrol Dial Transplant 22: 1369-1376, 2007
23. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G: Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932-937, 2007
24. Pansini F, Bonifati C, Manno C, Schena FP: Rituximab induces complete remission in a case of membranous nephropathy associated with hepatitis C virus-related infection. Nephrol Dial Transplant 22: 3674-3676, 2007
25. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008 (Pubitemid 350273646)
26. Ferrannini M, Vischini G, Di Daniele N: Rituximab in membranous nephropathy after haematopoietic stem cell transplantation. Nephrol Dial Transplant 23: 2700-2701; author reply 2701, 2008
27. Troxell ML, Pilapil M, Miklos DB, Higgins JP, Kambham N: Renal pathology in hematopoietic cell transplantation recipients. Mod Pathol 21: 396-406, 2008
28. Weclawiak H, Ribes D, Guilbeau-Frugier C, Touchard G, Kamar N, Mehrenberger M, Modesto A, Rostaing L: Relapse of membranous glomerulopathy after kidney transplantation: Sustained remittance induced by rituximab. Clin Nephrol 69: 373-376, 2008 (Pubitemid 351663173)
29. Pixley JS, Wolf BJ, O'Neill W: Membranous glomerulopathy associated with rheumatoid arthritis may respond to rituximab. Scand J Rheumatol 37: 313-314, 2008
30. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G: Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 3: 1652-1659, 2008
31. Ponticelli C, Zucchelli P, Passerini P, Cesana B: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 327: 599-603, 1992
32. Donadio JV Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP: Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 33: 708-715, 1988
33. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993 (Pubitemid 23188821)
34. Hogan SL, Muller KE, Jennette JC, Falk RJ: A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25: 862-875, 1995
35. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007
36. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, et al.: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13, 1989 (Pubitemid 19033056)
37. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998
38. Cheson BD, Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359: 613-626, 2008
39. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[2 Suppl 1]: S1-S266, 2002
40. Kranick SM, Mowry EM, Rosenfeld MR: Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 69: 704-706, 2007 (Pubitemid 47256017)
41. Rituxan warning. FDA Consum 41: 3, 2007
42. Newton P, Aldridge RD, Lessells AM, Best PV: Progressive multifocal leukoencephalopathy complicating systemic lupus erythematosus. Arthritis Rheum 29: 337-343, 1986
43. Ahmed F, Aziz T, Kaufman LD: Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. J Rheumatol 26: 1609-1612, 1999
44. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368, 2005 (Pubitemid 41132340)
45. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369-374, 2005 (Pubitemid 41132341)
46. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375-381, 2005
47. Molloy ES, Calabrese LH: Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8: 144-146, 2008
48. Dear Doctor letter (Cellcept®, mycophenolate mofetil). Nutley, NJ: Roche Laboratories Inc, 2008
49. Makker SP, Kanalas JJ: Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy. J Immunol 142: 3406-3410, 1989